Exabis Library
Welcome to the e-CCO Library!
P575: Vedolizumab trough levels predict clinical outcomes in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P576 The value of small bowel capsule endoscopy in the change of therapeutic management in patients with established Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P576: Could the hyperbaric oxygen therapy be an effective adjuvant therapy for fistulising Crohn's disease?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P576: Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CD
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P576: Impact of improved access to biologic therapies and physician engagement on excess steroid exposure: Results from a UK audit of 3561 patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P576: Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P576: Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn’s disease patients treated with anti-TNF: a prospective multi-centre study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P576: Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P577 Ustekinumab in actual clinical practice: our centre experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P577: “Treat to target” recommendations in ulcerative colitis in practice: clinician perceptions and potential barriers
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P577: A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P577: A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P577: Drug Induced Liver Injury (DILI) secondary to biologic therapy in IBD: ECCO- CONFER Series
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P577: Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P577: Withdrawal of thiopurines in patients with Ulcerative Colitis in remission
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P578 Inter-observer agreement of an expert panel for gastrointestinal ultrasound in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P578: Adriatic-Balkan regional survey on COVID-19 in Inflammatory Bowel Disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P578: Evolution of Crohn's disease treatment in clinical practice: a 25 year single centre cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P578: Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P578: Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM